March 6, 2020

Corporate Relationship Department
M/s. BSE Ltd
Dalal Street, Fort
Mumbai- 400 001

Scrip Code: 524816

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai -400 051

Scrip Code: NATCOPHARM

Dear Sir

Please find enclosed the Press Release for your information.

Thanking you

Yours faithfully
For NATCO Pharma Limited

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)
USFDA COMPLETES INSPECTION OF NATCO’s KOTHUR FORMULATION FACILITY

Hyderabad, India, March 6th, 2020

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce completion of a Pre-Approval inspection from the United States Food and Drug Administration (USFDA) for its Formulation facility in Kothur Village, near Hyderabad, India, which was conducted from 2nd March to 6th March, 2020.

At the end of the inspection, the facility received a single observation related to equipment qualification of a co-mill used in the process that had operating speed slightly outside the qualification range. The company believes that this is a minor observation and can be addressed within a short period of time.

The company will provide due justification and corrective action plan within the next 15 working days to address this observation.

Forwarded for favour of publication

For NATCO Pharma Limited

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)